Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New EU-funded Consortium to Develop Fully Personalized Cancer Vaccines

Published: Friday, July 05, 2013
Last Updated: Thursday, July 04, 2013
Bookmark and Share
Multinational clinical trial treating glioblastoma patients with fully personalized therapeutic vaccines planned to start in 2014.

A highly innovative project supported by a €6 million European Union Framework 7 (EU FP7) program grant to develop a novel class of therapeutic cancer vaccines is now under way.

The Glioma Actively Personalized Vaccine Consortium (GAPVAC) is the first EU-funded initiative aimed at clinically developing biomarker-guided actively personalized vaccines (APVACs) to treat cancer patients.

The consortium consists of 14 organizations from the biotech industry and academia with cutting-edge expertise in cancer vaccine development.

The consortium will be led by immatics biotechnologies GmbH (Coordinator) and BioNTech AG (Vice Coordinator). Both companies are located in Germany and are dedicated to a biomarker-guided approach to fight cancer.

The project
The GAPVAC project is designed to create, manufacture and develop actively personalized vaccines (APVACs) tailored for each patient based on the individual aspects of the patient’s tumor and immune system.

The latest technologies, including next-generation sequencing (NGS), high-sensitivity mass spectrometry and innovative immunomonitoring approaches, will be combined to generate an optimal therapy for the individual patient.

GAPVAC will address the high unmet medical need in glioblastoma, an aggressive form of brain cancer with poor prognosis, where the limited treatments available today have minimal effect on overall survival.

The project aims to show that APVACs are well tolerated and induce a strong and specific immune response against cancer. Furthermore, the partners will demonstrate that this novel personalized approach is feasible.

The clinical trial
immatics and BioNTech will jointly take this actively personalized approach to immunotherapy into clinical development.

At the core of the GAPVAC project is a phase 1 clinical trial which will enroll up to 30 newly diagnosed glioblastoma patients and is expected to start in 2014.

Glioblastoma patients will be repetitively immunized with a vaccine specifically prepared for each individual. This actively personalized vaccine will be administered in addition to standard chemotherapy after surgery and initial radiochemotherapy are completed.

The clinical trial will be led by chief investigator Prof. Dr. Wolfgang Wick, University of Heidelberg, and co-led by Prof. Dr. Pierre-Yves Dietrich, University of Geneva, both internationally recognized experts in the treatment and immunology of brain cancer.

The partners
immatics will use its unique antigen discovery engine XPRESIDENT™ to generate a warehouse of tumor-associated peptides (TUMAPs) from which the most suitable for each patient are selected based on transcriptomic and peptidomic analysis to create the first of two APVACs applied to the patient.

BioNTech AG will add proprietary glioblastoma-expressed tumor-associated antigens to the peptide warehouse. immatics and BioNTech will use their mass spectrometry and next-generation sequencing (NGS) expertise, respectively, to identify immunogenic tumor mutations and generate a blueprint for the personalized vaccine that will include patient-specific tumor mutated peptides.

For the first time, BioNTech has demonstrated that the integrated use of NGS for genome-wide mutation identification (the “mutanome”) followed by mutation-targeting vaccination is feasible and leads to tumor control in pre-clinical models.

The APVAC “on-demand” manufacturing will be performed by the GMP-unit at the Department of Immunology (led by Prof. Dr. Hans-Georg Rammensee), University of Tuebingen. The complex peptide warehouse will be manufactured by BCN Peptides in Spain, an enterprise focused on peptide synthesis for clinical use.

In addition, ten academic partners from Europe and the US have joined the consortium to apply the APVACs to their patients as well as contributing to the project with their own research.

These will be: Eberhard Karls University Tuebingen (Germany), Beatson West of Scotland Cancer Centre (Scotland), Universities Hospital Geneva (Switzerland), Universities Hospital Heidelberg (Germany), Herlev Hospital/ Rigshospitalet (Denmark), Leiden University Medical Centre (The Netherlands), University of Pittsburgh Cancer Institute (US), University Southampton (UK), Technion (Israel) and Vall d’Hebron University Hospital (Spain).

The clinical trial will be accompanied by an extensive biomarker program led by the Association of Cancer Immunotherapy (CIMT), a non-profit organization dedicated to the advancement of cancer vaccines, and immatics to confirm the mechanism-of-action and to identify biomarker signature candidates predicting which patients are most likely to benefit from treatment with APVACs.

CIMT will also act as the dissemination platform and will contribute to the biomarker program and regulatory approach through its working parties.

Dr. Harpreet Singh, Chief Scientific Officer of immatics and Coordinator of the GAPVAC consortium, said: “GAPVAC represents an exciting step forward as the first project exploring actively personalized therapeutic cancer vaccines at a European level. Unlike other approaches, this consortium is looking at the specific characteristics of each patient’s disease. If successful, this novel approach could create a completely new way to treat cancer. Such a unique approach is only possible by combining a variety of the latest technological innovations and by joining forces with superb biotechnology companies and academic institutions - by partners who share a dedication for the personalization of therapy for the benefit of cancer patients.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

immatics Appoints Peter Chambré as Chairman
Peter Chambré will replace Thomas Widmann.
Monday, November 12, 2012
immatics’ Renal Cancer Vaccine IMA901 Completes Phase 3 Patient Recruitment
Drug is granted US orphan drug designation by the FDA.
Thursday, November 08, 2012
immatics Announces Publication of IMA901 Cancer Vaccine Data in Nature Medicine
Paper highlights clinical and immunological activity of IMA901 in renal cell carcinoma (RCC).
Thursday, August 16, 2012
Scientific News
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
'Poison Pill' Fed to Deadly Virus
Researchers have created a genetic modification within a virus (with funny name), rendering it unable to replicate, mutate or cause illness.
World First Alzheimer's Vaccine Breakthrough
Researchers have made a breakthrough discovery towards an effective vaccine for Alzheimer's by targeting associated proteins.
Immunotherapy Drug Combo Targets Cancer
Mayo Clinic researchers identify potential immunotherapy drug combination that shows therapeutic effects against advanced and metastatic cancers.
Study Shows Sandoz Biosimilar Equivalent to Originator Drug
New data shows Sandoz biosimilar candidate has equivalent efficacy to originator etanercept following comparison in psoriasis.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!